Market Capitalization

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

After repeated hurricane shutdowns, St. Petersburg invests $1M in innovative flood panels to keep its critical water facilities running.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

With its Moda-flx system cleared by the FDA, Diality hires M&A expert Peter Donato to navigate the path to commercialization in the $92B dialysis market.

With overwhelming bondholder support, the media giant gains financial flexibility for shareholder returns while tightening protections for its creditors.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.

Industrial packaging giant Greif rewards shareholders, but a closer look at its finances and dual-class stock reveals a company in major transition.

The AI health platform's latest acquisition integrates a specialized pregnancy app, promising a new era of proactive, data-driven maternal care for families.

Toymaker JAKKS Pacific launches an ambitious new platform targeting the multi-billion dollar anime, manga, and creator markets. Can it beat the competition?

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

Dubai's office market is booming as AHS Tower sells out during development, setting a new benchmark for wellness-focused, luxury commercial spaces.

China’s pioneering EV charging firm NaaS faces a delisting threat from Nasdaq, battling not just low market value but also negative equity and major losses.

First Horizon's financial and credit chiefs will present at a key conference. We dive into their strategy amid industry headwinds and strong 2025 results.

Malaysian solar firm FGL faces delisting after a reverse stock split, meant to save its listing, backfired and wiped out its public share float.

Amid soaring demand, Cleanroom Film & Bags adds a high-speed production line, reinforcing the supply chains for vital medical and semiconductor industries.